Abstract:Recent studies have shown that the expression of ENPP1 is related to differentiation, death, dissemination and chemosensitivity of tumor cells. So far, there is no research in ovarian carcinoma. This study aimed at exploring the role of ENPP1 gene in ovarian carcinoma, the relationship with prognostic indicators and chemotherapy resistance, and investigates the possibility of molecular targeted therapy. The expression of ENPP1 in 41 normal ovarian epithelial tissues, 97 ovarian serous cystadenoma and 103 HGSOC tissues was detected by IHC. In ovarian cancer tissues and ovarian cancer cell lines, mRNA and protein expression of ENPP1 was determined by qRT-PCR and Western blot. The ENPP1 expression was knockdowned by siRNA. Cell proliferation was measured with the BrdU Cell Proliferation ELISA. Cell migration and invasion were detected by Wound-Healing, Transwell migration and Matrigel invasion assay. Caspase 3 activity was determined by the CaspACE. The expression of EMT markers such as E-cadherin, N-cadherin, and Vimentin was measured, and the expression of PCNA and MMP9 was also be detected. The results showed that the expression of ENPP1 was significantly increased in high-grade ovarian serous carcinoma, the number of strong expression was 85.4% (22.3%+63.1%) and only 1.03% (1.03%+0.0%) in serous cystadenoma, but no in normal ovarian epithelium (P< 0.05). And the stronger the expression of ENPP1, the later the FIGO stage and the poorer differentiation of cells (P = 0.001 or <0.001, respectively). However, no correlation was found between the expression of ENPP1 and chemosensitivity. ENPP1 was also highly expressed in ovarian cancer tissues and in epithelial ovarian cancer cell lines (A2780, CaoV3, OVCAR3, SKOV3 and 3ao). After down-regulation of ENPP1 expression by RNA interference, the cell proliferation, migration and invasion of ovarian cancer cell decreased significantly, the expression of apoptosis related gene caspase 3 increased significantly, while the expression of PCNA and MMP9 was significantly down regulated. In addition, EMT biological characteristics of A2780 and SKOV3 cells were also inhibited. In summary, the increased expression of ENPP1 may be related to the occurrence of HGSOC, and indicate that the disease progresses rapidly and the prognosis is poor. ENPP1 may be considered as a potential molecular therapeutic target.

Enolase-phosphatase 1 Acts As an Oncogenic Driver in Glioma.

High Expression of ENPP1 in High-Grade Serous Ovarian Carcinoma Predicts Poor Prognosis and As a Molecular Therapy Target.

ENO3 Promotes Colorectal Cancer Progression by Enhancing Cell Glycolysis

EN1 Regulates Cell Growth and Proliferation in Human Glioma Cells Via Hedgehog Signaling

ENO1 and Cancer

Enolase 1 Stimulates Glycolysis to Promote Chemoresistance in Gastric Cancer.

The Moonlighting Function of Glycolytic Enzyme Enolase-1 Promotes Choline Phospholipid Metabolism and Tumor Cell Proliferation

Enolase1 Overexpression Regulates the Growth of Gastric Cancer Cells and Predicts Poor Survival

Alpha-enolase promotes cell glycolysis, growth, migration, and invasion in non-small cell lung cancer through FAK-mediated PI3K/AKT pathway

Enolase-1 is A Therapeutic Target in Endometrial Carcinoma

Role of ENO1 and its targeted therapy in tumors

Overexpression of Osteopontin Induces Angiogenesis of Endothelial Progenitor Cells Via the Avβ3/pi3k/akt/enos/no Signaling Pathway in Glioma Cells

Enolase 1, a Moonlighting Protein, as a Potential Target for Cancer Treatment

ENO1 Promotes Immunosuppression and Tumor Growth in Pancreatic Cancer.

O-GlcNAcylation of enolase 1 serves as a dual regulator of aerobic glycolysis and immune evasion in colorectal cancer.

EEF1E1 Promotes Glioma Proliferation by Regulating Cell Cycle Through PTEN/AKT Signaling Pathway.

ENO1 contributes to the gemcitabine resistance of pancreatic cancer through the YAP1 signaling pathway

Integration of Metabolomics and Expression of Enolase-Phosphatase 1 Links to Hepatocellular Carcinoma Progression.

Enolase 1 Regulates Gastric Cancer Progression through the Electron Transfer Flavoprotein Dehydrogenase Gene

WW domain-binding protein 2 acts as an oncogene by modulating the activity of the glycolytic enzyme ENO1 in glioma

Engrailed 2 (EN2) acts as a glioma suppressor by inhibiting tumor proliferation/invasion and enhancing sensitivity to temozolomide